ArticleJournal of military, veteran and family health2023
A history and future of psychedelics: The case of the Canadian military.
Article in Journal of military, veteran and family health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2017, the U.S. Food and Drug Administration granted breakthrough therapy status to 3,4-methylenedioxy-methamphetamine (MDMA) for posttraumatic stress disorder (PTSD) based partially on clinical trials with American Veterans. This drug, known popularly as ecstasy, generated better results for individuals suffering from PTSD than any other available therapies. Other trials focused on Veterans and those in active military service, alongside emerging studies with first responders, police officers, and people with complex trauma-based disorders. Although psychedelic drugs, especially psilocybin mushrooms and MDMA, are once again the subject of a variety of clinical trials that span beyond military medicine and PTSD, the connection between psychedelics and military health present particular challenges and opportunities when it comes to integrating psychedelics into the Canadian military health system. This article examines the history of psychedelics in Canada, underscoring the importance of how historical understandings of both military-based trauma and psychedelics influenced the reception of psychedelics as therapeutic options today.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.